Abstract:Objectives To detect the early subclinical myocardial injury during and shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma by two-dimensional speckle tracking imaging and high sensitive cardiac troponin T (hs-cTnT) and to investigate whether alterations of myocardial strains and high sensitive cardiac troponin T could predict future cardiac dysfunction in patients after epirubicin exposure. Methods Seventy-five patients aged 53.9 ± 13.8 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with anthracycline were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion. After 4–6 months of chemotherapy, echocardiography was followed up. Levels of cTnT were detected with a highly sensitive assay. Longitudinal (LS), circumferential (CS) and radial strain (RS) were calculated using two-dimensional speckle tracking echocardiography. Left ventricular ejection fraction (LVEF) was analysed by real-time 3D echocardiography. Cardiotoxicity was defined according to the guidelines (Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity, CREC) as a reduction of the left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%. Results LVEF remained stable and within normal limits in the whole course of chemotherapy. However it was decreased from 65.0 ± 3.8% at baseline to 60.8 ± 4.9% during follow-up (p = 0.000). Fourteen patients (18.67%) developed cardiotoxicity 4–6 months after treatment. Global LS (-18.5 ± 1.7% vs -16.5 ± 1.9%), CS (-20.9 ± 2.9% vs -19.3 ± 3.5%), RS (39.2 ± 6.4% vs 35.3 ± 5.2%) were markedly reduced and cTnT was elevated from 0.0010 ± 0.0020 ng/ml to 0.0063 ± 0.0089 ng/ml (p all<0.01) at the completion of the third cycle of chemotherapy compared with baseline values. The correlation between the increment of cTnT levels and percentage of global LS deduction was good (rho = 0.60, p < 0.01), and percentage of CS and RS decrease was modest (rho = 0.31, -0.29, respectively, p all <0.01). A >15.9% decrease in longitudinal strain ( sensitivity: 86%, specificity: 75%, AUC = 0.815, P = 0.001) and a >0.004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%, AUC = 0.757, P = 0.005) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity. The decrease of longitudinal strain between baseline and the third cycle of chemotherapy remained the only independent predictor of cardiotoxicity (p = 0.000). Conclusions Two-dimensional speckle tracking imaging combined with high sensitive cTnT may provide a reliable and accurate non-invasive method to detect subtle myocardial injury and to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy. The decrease of longitudinal strain is the only independent predictor of cardiotoxicity.

Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment

Significance of detecting cardiac troponin I and creatine kinase MB in critically Ill children without primary cardiac illness

Correlation of Plasma MiR-146a,MiR-223 Levels with the Prognosis of Childhood with Acute Lymphoblastic Leukemia

GW24-e1764 Speckle Tracking Imaging Combined with High Sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Anthracycline-based Chemotherapy

Two‐dimensional Speckle Tracking Echocardiography Combined with High‐sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Epirubicine‐based Chemotherapy

High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

[Evaluation of Early Monitoring of Cardiotoxicity Induced by Anthracyclines].

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

P2429Echocardiographic Tei Index Combined with Serum High-Sensitivity Troponin T Assay for Early Diagnosis of Anthracycline-Induced Cardiotoxicity

Circulating and Cardiac Tissue miRNAs in Children with Dilated Cardiomyopathy

Estimation of the value of echocardiographic Tei index combined with serum high-sensitivity cardiac troponin T assay in early diagnosis of anthracycline-induced cardiotoxicity

Early Anthracycline-Induced Cardiotoxicity Monitored by Echocardiographic Doppler Parameters Combined with Serum Hs-Ctnt.

Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy

Cardiac miRNA expression during the development of chronic anthracycline-induced cardiomyopathy using an experimental rabbit model

Myocardial Deformation Imaging by Speckle-Tracking Echocardiography for Assessment of Cardiotoxicity in Children during and after Chemotherapy: A Systematic Review and Meta-Analysis

Assessment of left heart dysfunction to predict doxorubicin cardiotoxicity in children with lymphoma

Evaluation of Cardiac Electrophysiological Examination for Anthracycline Related Early Cardiotoxicity in Children with Leukemia or Solid Tumor

Cardiac troponin I in children with left-to-right shunt congenital heart disease

Early Detection of the Cardiotoxicity Induced by Chemotherapy Drug Through Two-Dimensional Speckle Tracking Echocardiography Combined with High-Sensitive Cardiac Troponin T

Signature Of Circulating Micrornas As Potential Biomarkers In Vulnerable Coronary Artery Disease

Change of plasma microRNA-208 level in acute myocardial infarction patients and its clinical significance